Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CARA NASDAQ:CRON TSE:ITH NASDAQ:SLS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCARACara Therapeutics$15.19$8.13▼$19.08$24.33M0.4122,224 shs237,144 shsCRONCronos Group$2.55+2.8%$2.27$1.60▼$2.77$949.58M1.123.49 million shs2.02 million shsITHInternational Tower Hill MinesC$2.12-3.2%C$1.67C$0.60▼C$2.29C$440.72M0.91461531,077 shs28,432 shsSLSSELLAS Life Sciences Group$1.86-2.1%$1.81$0.77▼$2.27$200.07M2.541.82 million shs1.39 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCARACara Therapeutics0.00%0.00%0.00%0.00%+43.01%CRONCronos Group+2.82%+2.00%+10.87%+30.10%+15.38%ITHInternational Tower Hill Mines-3.20%-4.50%+9.28%+66.93%+207.25%SLSSELLAS Life Sciences Group-2.11%+1.64%+17.72%+24.00%+53.72%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCARACara Therapeutics$15.19$8.13▼$19.08$24.33M0.4122,224 shs237,144 shsCRONCronos Group$2.55+2.8%$2.27$1.60▼$2.77$949.58M1.123.49 million shs2.02 million shsITHInternational Tower Hill MinesC$2.12-3.2%C$1.67C$0.60▼C$2.29C$440.72M0.91461531,077 shs28,432 shsSLSSELLAS Life Sciences Group$1.86-2.1%$1.81$0.77▼$2.27$200.07M2.541.82 million shs1.39 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCARACara Therapeutics0.00%0.00%0.00%0.00%+43.01%CRONCronos Group+2.82%+2.00%+10.87%+30.10%+15.38%ITHInternational Tower Hill Mines-3.20%-4.50%+9.28%+66.93%+207.25%SLSSELLAS Life Sciences Group-2.11%+1.64%+17.72%+24.00%+53.72%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCARACara Therapeutics 0.00N/AN/AN/ACRONCronos Group 0.00N/AN/AN/AITHInternational Tower Hill Mines 0.00N/AN/AN/ASLSSELLAS Life Sciences Group 3.00Buy$7.00276.34% UpsideCurrent Analyst Ratings BreakdownLatest ITH, CARA, CRON, and SLS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/16/2025SLSSELLAS Life Sciences GroupMaxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$4.00 ➝ $7.00(Data available from 9/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCARACara Therapeutics$7.14M0.00N/AN/A$12.58 per share0.00CRONCronos Group$130.28M7.49$0.00 per share5,329.67$2.90 per share0.88ITHInternational Tower Hill MinesN/AN/AC$0.09 per share22.50C$0.29 per shareN/ASLSSELLAS Life Sciences Group$1M195.86N/AN/A$0.13 per share14.31Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCARACara Therapeutics-$118.51M-$21.01N/AN/AN/A-1,099.76%-367.97%-107.43%N/ACRONCronos Group$41.08M$0.0551.0085.00N/A14.19%-3.78%-3.62%11/11/2025 (Estimated)ITHInternational Tower Hill Mines-C$2.36M-C$0.02N/A∞N/AN/A-5.82%-3.65%N/ASLSSELLAS Life Sciences Group-$30.88M-$0.32N/AN/AN/AN/A-132.51%-92.79%11/12/2025 (Estimated)Latest ITH, CARA, CRON, and SLS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025SLSSELLAS Life Sciences Group-$0.0767-$0.07+$0.0067-$0.07N/AN/A8/7/2025Q2 2025CRONCronos Group-$0.02-$0.10-$0.08-$0.10$45.73 million$33.46 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCARACara TherapeuticsN/AN/AN/AN/AN/ACRONCronos GroupN/AN/AN/AN/AN/AITHInternational Tower Hill MinesN/AN/AN/AN/AN/ASLSSELLAS Life Sciences GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCARACara TherapeuticsN/A4.774.71CRONCronos GroupN/A24.6523.53ITHInternational Tower Hill MinesN/A10.3730.48SLSSELLAS Life Sciences GroupN/A4.914.91Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCARACara Therapeutics44.66%CRONCronos Group8.71%ITHInternational Tower Hill Mines6.08%SLSSELLAS Life Sciences Group17.38%Insider OwnershipCompanyInsider OwnershipCARACara Therapeutics3.10%CRONCronos Group6.90%ITHInternational Tower Hill Mines0.51%SLSSELLAS Life Sciences Group1.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCARACara Therapeutics804.57 million4.43 millionOptionableCRONCronos Group450382.89 million356.47 millionOptionableITHInternational Tower Hill Mines220207.89 millionN/ANot OptionableSLSSELLAS Life Sciences Group10105.30 million104.03 millionNot OptionableITH, CARA, CRON, and SLS HeadlinesRecent News About These CompaniesAnson Funds Management LP Purchases 6,386,829 Shares of SELLAS Life Sciences Group, Inc. $SLSAugust 26, 2025 | marketbeat.comSELLAS Life Sciences Group Sees Unusually High Options Volume (NASDAQ:SLS)August 20, 2025 | marketbeat.comSellas Life Sciences: SLS009's Phase 2 Sets Up A Promising 2026August 19, 2025 | seekingalpha.comSELLAS Life Sciences Group (NASDAQ:SLS) Issues Earnings ResultsAugust 14, 2025 | marketbeat.comSellas Life Sciences Reports Q2 2025 Financial ResultsAugust 13, 2025 | msn.comSellas Life Sciences reports Q2 EPS (7c), consensus (8c)August 12, 2025 | msn.comSELLAS Life Sciences Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateAugust 12, 2025 | finance.yahoo.comSELLAS Life Sciences Announces Independent Data Monitoring Committee Periodic Review and Positive Recommendation to Continue Pivotal Phase 3 REGAL Trial of GPS in AML Without ...August 9, 2025 | finance.yahoo.comSELLAS Life Sciences Announces Independent Data Monitoring Committee Periodic Review and Positive Recommendation to Continue Pivotal Phase 3 REGAL Trial of GPS in AML Without ModificationAugust 7, 2025 | globenewswire.comSELLAS Life Sciences Group (SLS) Upgraded to Buy: What Does It Mean for the Stock? (Revised)July 31, 2025 | zacks.comSellas Flat on Trial SuccessJuly 16, 2025 | baystreet.caSELLAS gains as mid-stage trial for leukemia drug succeedsJuly 16, 2025 | msn.comSELLAS Life Sciences Group Welcomes Dr. Linghua Wang to Scientific Advisory Board - NasdaqJuly 9, 2025 | nasdaq.comSellas Life Sciences appoints Linghua Wang to Scientific Advisory BoardJuly 7, 2025 | msn.comSELLAS Life Sciences Appoints Linghua Wang, MD, PhD, to Scientific Advisory BoardJuly 7, 2025 | globenewswire.comSELLAS Life Sciences to be Added to Russell 3000® and Russell 2000® IndexesJune 24, 2025 | finance.yahoo.comGalena Biopharma (SLS) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo FinanceJune 24, 2025 | finance.yahoo.comGalena Biopharma (SLS) Upgraded to Buy: What Does It Mean for the Stock?June 23, 2025 | zacks.comSellas Life Sciences: Tons Of Completed StudiesJune 17, 2025 | seekingalpha.comNostrand Robert L. Van Purchases 10,000 Shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) StockJune 14, 2025 | insidertrades.comSELLAS Life Sciences Expands Scientific Advisory Board with Addition of Two World-Renowned Hematology and Oncology ExpertsJune 5, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Companies That Will Profit From Trump's Semiconductor TariffsBy Jordan Chussler | August 14, 2025Amazon Stock Sets Up for Breakout After Bullish CrossoverBy Sam Quirke | August 21, 2025Broadcom Named in Apple’s $100B U.S. Investment PlanBy Leo Miller | August 22, 20254 Stocks That May Get a Big Earnings Bump This WeekBy Nathan Reiff | August 11, 2025ITH, CARA, CRON, and SLS Company DescriptionsCara Therapeutics NASDAQ:CARACara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.Cronos Group NASDAQ:CRON$2.55 +0.07 (+2.82%) Closing price 09/9/2025 04:00 PM EasternExtended Trading$2.54 -0.01 (-0.39%) As of 09/9/2025 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.International Tower Hill Mines TSE:ITHC$2.12 -0.07 (-3.20%) As of 09/9/2025 04:00 PM EasternInternational Tower Hill Mines Ltd is a mining company. It is engaged in the acquisition, exploration, and development of mineral properties. The company holds interests in an advanced stage exploration project namely the Livengood Gold Project. It is located approximately 70 miles northwest of Fairbanks, Alaska in the Tolovana mining district within the Tintina gold belt. The project property consists of land leased from the Alaska mental health trust, a number of smaller private mineral leases, Alaska state mining claims purchased or located by the company and patented ground held by the company.SELLAS Life Sciences Group NASDAQ:SLS$1.86 -0.04 (-2.11%) Closing price 09/9/2025 04:00 PM EasternExtended Trading$1.86 0.00 (0.00%) As of 09/9/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Is Qualcomm Tesla’s Next Rival in Autonomous Driving? Casey’s General Stores: Investors Win With CASY at the Bat Should You Buy Figma Stock After Its 55% Post-IPO Drop? Ulta Beauty Stock: Strong Growth, Short-Term Volatility Ahead Joby's Stock Is Quiet, But a Storm of Catalysts Is Brewing The Quiet Before the Catalyst: Vertical Aerospace's Next Move Novartis' Moonshot Cancer Therapy Could Be Future Growth Driver Insiders Sell These High-Quality Stocks: Why Investors Shouldn’t Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
